Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 227-237 , February 2006

In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models

Received 31 March 2005 ,Revised 17 October 2005 ,Accepted 20 October 2005.

References 

  1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:163–176
  2. Cotran RS, Kumar V, Collins T. Robbins pathologic basis of disease. 6th ed.. Philadelphia: W.B. Saunders; 1999;
  3. Matrisian LM. Metalloproteinases and their inhibitors in tissue remodeling. Trends Genet. 1990;6:121–125
  4. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1990;5:2145–2154
  5. Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9:289–303
  6. Tryggvason K, Hoyhta M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987;907:191–217
  7. Tryggvason K. Type-IV collagenase in invasive tumors. Breast Cancer Res Treat. 1993;24:209–218
  8. Itoh T. Reduced angiogenesis and tumor progression in gelatinase — A deficient mice. Cancer Res. 1998;58:1048–1051
  9. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–490
  10. Vilinen P, Kahari V-M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157–166
  11. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinomas. Br J Cancer. 2003;89:1270–1275
  12. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat. 1999;58:287–293
  13. Talvensaari-Mattila A, Paakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat. 2001;65:55–61
  14. Bremer C, Tung C-H, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase activity. Nat Med. 2001;7:743–748
  15. Zheng Q-H, Fei X, DeGrado TR, Wang J-Q, Lee Stone K, Martinez TD, et al. Synthesis, biodistribution and micro-PET imaging of a potential cancer biomarker carbon-11 labeled MMP inhibitor (2R)-2-[[4-(6-fluorohex-1-ynyl)phenyl]sulfonylamino]-3-methylbutyric acid [11C]methyl ester. Nucl Med Biol. 2003;30:753–760
  16. Kulasegaram R, Giersing B, Page CJ, Blower PJ, Williamson RA, Peters BS, et al. In vivo evaluation of In-111-DTPA-N-TIMP-2 in Kaposi's sarcoma associated with HIV infection. Eur J Nucl Med. 2001;28:756–761
  17. Zheng Q-H, Fei X, Liu Z, Wang J-Q, Stone KL, Martinez TD, et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4′-[11C]methoxybiphenyl-4-sulfonylamino)-3-methoxyphenyl)sulfonyl]benzylamino]-3-methylbutanamide. Nucl Med Biol. 2004;31:77–85
  18. Oltenfreiter R, Staelens L, Lejeune A, Dumont F, Frankenne F, Foidart JM, et al. New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents. Nucl Med Biol. 2004;31:459–468
  19. Furumoto S, Takashima K, Kubota K, Ido T, Iwata R, Fukuda H. Tumor detection using 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl Med Biol. 2003;30:119–125
  20. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17:768–774
  21. Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol. 2004;31:337–344
  22. Medina OP, Kairemo K, Valtanen H, Kangasniem A, Kaukenen S, Ahonen I, et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res. 2005;25:33–42
  23. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl Med Biol. 1997;24:35–43
  24. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwartz SW, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-Octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res. 1999;5:3608–3616
  25. Connett JM, Anderson CJ, Guo L-W, Schwartz SW, Zinn KR, Rogers BE, et al. Radioimmunotherapy with a Cu-64 labeled monoclonal antibody: a comparison with Cu-67. Proc Natl Acad Sci U S A. 1996;93:6814–6818
  26. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, et al. In vivo evaluation of pretargeted Cu-64 for tumor imaging and therapy. J Nucl Med. 2003;44:1284–1292
  27. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margenau WH, Cutler CS, et al. The efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl Med Biol. 1997;24:35–43
  28. Atherton E, Sheppard RC. Solid phase peptide synthesis: a practical approach. Oxford (England): Oxford Univ. Press; 1989;
  29. Achilefu S, Jimenez HN, Dorshow RB, Bugaj JE, Webb EG, Wilhelm RR, et al. Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J Med Chem. 2002;45:2003–2015
  30. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol. 2000;35:479–485
  31. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-labeled octreotide conjugates. J Nucl Med. 1995;36:2315–2325
  32. Beekman B, Drijfhout JW, Bloemhoff W, Ronday HK, Tak PP, Koppele JM. Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media. FEBS Lett. 1996;390:221–225
  33. Bickett DM, Green MD, Berman J, Dezube M, Howe AS, Brown PJ, et al. A high throughput fluorogenic substrate for interstitial collagenase (MMP-1) and gelatinase (MMP-9). Anal Biochem. 1993;212:58–64
  34. Medina OP, Soderlund T, Laakkonen LJ, Tuominen EKJ, Koivunen K, Kinnunen PKJ. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001;61:3978–3985
  35. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, et al. Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci. 1994;732:315–323
  36. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, et al. Platelet and osteoclast beta 3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003;100:14205–14210
  37. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990;20:717–721
  38. Cherry SR, Shao Y, Silverman RW, Meadors K, Siegel S, Chatziioannou A, et al. MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci. 1997;44:1161–1166
  39. Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging. 2003;30:737–747
  40. Gonzalez-Avila G, Ituria C, Vadillo-Ortega F, Ovalle C, Montano M. Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology. 1998;66:196–204
  41. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, et al. Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci. 1994;732:315–323
  42. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465–1474
  43. Eckelman W. Developing a successful imaging probe: an overview: Society of Nuclear Medicine 52nd Annual Meeting, Toronto, Canada, 2005. http://interactive.snm.org/index.cfm?PageID=3902&RPID=3902&A=11&B=4692005;
  44. Eckelman W. The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals. Nucl Med Biol. 1994;21:759–769
  45. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res. 2001;21:3821–3828
  46. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alpha v beta 3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:9482–9487
  47. Tester AM, Waltham M, Oh S-J, Bae S-N, Bills MM, Walker EC, et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 2004;64:652–658
  48. Medina OP, Soderlund T, Laakkonen LJ, Tuominen EKJ, Koivunen E, Kinnunen PKJ. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001;61:3978–3985
  49. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol. 2000;34:148–155
  50. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem. 2002;45:469–477

PII: S0969-8051(05)00271-4

doi: 10.1016/j.nucmedbio.2005.10.011

Nuclear Medicine and Biology
Volume 33, Issue 2 , Pages 227-237 , February 2006

Article Tools

* Image Usage & Resolution